Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-23T03:05:13.704Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of armodafinil on reducing excessive sleepiness in patients with shift work disorder: A systematic review protocol

Published online by Cambridge University Press:  13 August 2021

J. Correia ,
P. Silva ,
F. Mendes ,
A.R. Ferreira  and
L. Fernandes
J. Correia*
Affiliation:
Medical Student, Faculty of Medicine of Porto University, Porto, Portugal, Portugal
P. Silva
Affiliation:
Medical Student, Faculty of Medicine of Porto University, Porto, Portugal, Portugal
F. Mendes
Affiliation:
Medical Student, Faculty of Medicine of Porto University, Porto, Portugal, Portugal
A.R. Ferreira
Affiliation:
Cintesis – Center For Health Technology And Services Research; Psychiatry Service Of Centro Hospitalar Universitário De São João; Department Of Clinical Neuroscience And Mental Health, Faculty of Medicine of Porto University, Porto, Portugal, Portugal
L. Fernandes
Affiliation:
Cintesis – Center For Health Technology And Services Research; Psychiatry Service Of Centro Hospitalar Universitário De São João; Department Of Clinical Neuroscience And Mental Health, Faculty of Medicine of Porto University, Porto, Portugal, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Previous studies have demonstrated that night-shift work is associated with adverse effects impacting physical and psychological health, including the Shift Work Disorder (SWD). SWD is a circadian rhythm disorder characterized by sleepiness and insomnia, resulting from working a shift other than the traditional daytime-shift. Armodafinil, a modafinil longer-lasting R-isomer, is approved for SWD treatment. Due to its pharmacodynamic profile, it may result in more sustained wakefulness during night-shifts than Modafinil.

Objectives

To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the efficacy of Armodafinil vs Modafinil and/or placebo on reducing SWD excessive sleepiness.

Methods

Will follow PRISMA guidelines. A systematic search will be conducted on PubMed, Web of Science, Scopus and ClinicalTrials.gov databases. RCTs comparing Armodafinil with Modafinil and/or Placebo for SWD treatment will be included. No language nor date restrictions will be applied. Outcomes of interest are prespecified as follows: the primary endpoint will be objective sleepiness; secondary endpoints will include subjective sleepiness, adverse effects, awareness, reaction time, memory and cognition. Retrieved studies will be independently screened for eligibility by two reviewers. Disagreements will be solved by consensus or by a third reviewer. Primary studies methodological quality will be assessed and data extracted independently using a standardized extraction-form.

Results

Data will be described and reported as narrative text and summary tables. Heterogeneity of the included studies will be assessed and, if possible, a meta-analysis will be conducted.

Conclusions

It is expected that this systematic review and meta-analysis favours Armodafinil over Modafinil and placebo in the treatment of SWD.

Disclosure

No significant relationships.

Keywords

ArmodafinilShift Work DisorderSleepinessSistematic Review
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S793
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.